Drug Profile

BCP 019

Alternative Names: BCP-019

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Alaska Fairbanks
Developer BeCool Pharmaceutics
Class Cardiovascular therapies; Small molecules
Mechanism of Action Adenosine A1 receptor agonists; Adenosine A1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Heart arrest

Highest Development Phases

No development reported Heart arrest

Most Recent Events

28 Mar 2024 No recent reports of development identified for research development in Heart-arrest in USA
13 Feb 2020 BeCool Pharmaceuticals announces intention to complete IND enabling studies for a pre-IND meeting for Heart arrest prior to February 2020
13 Feb 2020 BeCool Pharmaceutics plans a phase II trial for Heart arrest in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com